Taltz Citrate-Free: The same active ingredient with significantly less injection site pain vs the original formulation1*
Psoriatic Arthritis Safety
Data at weeks 24 and 52
IN PSORIATIC ARTHRITIS TRIALS
Common adverse events in pooled SPIRIT-P1 and -P2 trials that occurred through week 522,3
Overall, the safety profile in patients with psoriatic arthritis (PsA) treated with Taltz is consistent with the safety profile in patients with plaque psoriasis (PsO). The exception is the higher frequency of influenza (Taltz=1.3%, placebo=0.4%) and conjunctivitis (Taltz=1.3%, placebo=0%) in the PsA safety population vs the plaque psoriasis (PsO) safety population.
IN PSORIATIC ARTHRITIS TRIALS
Adverse events of special interest from pooled SPIRIT-P1 and -P2 trials through week 522,4,5
Certain adverse events, such as MACE and malignancy, require longer observation periods and larger patient exposure to ascertain risk. Lilly is conducting continued long-term safety studies, including post-marketing studies, to continue to evaluate the safety of Taltz.
Pooled safety data from SPIRIT-P1 and SPIRIT-P2 clinical trials.
Patients with uncontrolled Ulcerative Colitis (UC) or Crohn's disease were excluded from the studies; however, patients with a personal or family history of UC/Crohn's were allowed in the study.
Long-term safety across Taltz1-4,7,8
Demonstrated with more than 5 years of data in 8,000+ adult patients across 23 trials
Consistent results in adult patients across PsA, PsO, and axSpA populations
AEs of Special Interest: IR per 100 PYs2-7
SELECT IMPORTANT SAFETY INFORMATION
Taltz is contraindicated in patients with a previous hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
Warnings and precautions include infections, pre-treatment evaluation for tuberculosis, hypersensitivity, inflammatory bowel disease, and immunizations. The most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.
Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
IMPORTANT SAFETY INFORMATION
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.
Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.
IX HCP ISI 07MAY2020